Special management considerations for propranolol use in breastfed infants of mothers taking antihypertensives

Pediatr Dermatol. 2020 May;37(3):537-540. doi: 10.1111/pde.14134. Epub 2020 Feb 28.

Abstract

Propranolol is approved for treatment of infantile hemangiomas (IH). IH proliferation coincides with the time when most women are breastfeeding, yet there are no reports describing the clinical effects on infants treated with propranolol while being nursed by mothers on oral antihypertensive medications. We describe two cases of breastfed infants, with mothers taking multiple antihypertensives of different drug classes, who were initiated on propranolol for IH treatment and discuss the theoretical risk of propranolol use in this setting.

Keywords: hemangiomas/vascular tumors; neonatal; pharmacology; systemic therapy; therapysystemic; vascular malformation.

Publication types

  • Case Reports

MeSH terms

  • Adrenergic beta-Antagonists / therapeutic use
  • Antihypertensive Agents
  • Breast Feeding
  • Female
  • Hemangioma*
  • Humans
  • Infant
  • Mothers
  • Propranolol / therapeutic use
  • Skin Neoplasms*
  • Treatment Outcome

Substances

  • Adrenergic beta-Antagonists
  • Antihypertensive Agents
  • Propranolol